By: IPP Bureau
Last updated : June 05, 2026 10:16 am
Company expands injectable portfolio with therapeutically equivalent version of Vimpat®, targeting a market valued at approximately $15.2 million annually
Glenmark Pharmaceuticals has announced the launch of Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials in the United States.
The product is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat Injection, 200 mg/20 mL (10 mg/mL), marketed by UCB Inc..
According to IQVIA sales data for the 12-month period ending April 2026, the Vimpat Injection market generated annual sales of approximately $15.2 million in the United States, highlighting a significant opportunity in the injectable anti-epileptic therapy segment
Marc Kikuchi, President & Business Head, North America said, “The launch of Lacosamide Injection USP reflects the disciplined execution of our strategy to build a broader, differentiated product portfolio in the United States.
“By expanding our injectable product portfolio, we are enhancing our ability to meet the evolving needs of healthcare providers while advancing our commitment to improving patient access to quality, affordable treatment options,” added Kikuchi.
The launch strengthens Glenmark’s presence in the US generics market and supports the company’s strategy of expanding its portfolio of complex and differentiated injectable products.
The addition of Lacosamide Injection USP is expected to further improve access to affordable treatment options for patients while providing healthcare providers with a high-quality alternative to the branded product.